Clinical Trial Update: Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating intravenous belimumab versus placebo for idiopathic membranous nephropathy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Membranous Nephropathy

Drugs mentioned

• Belimumab (belimumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Glomerulonephritis, Membranous | Phase 2 | Status: WITHDRAWN